Jazz Pharmaceuticals (JAZZ) Goodwill & Intangibles (2010 - 2026)

Jazz Pharmaceuticals' Goodwill & Intangibles history runs 17 years deep, the most recent figure standing at $6.0 billion for Q1 2026.

• On a quarterly basis, Goodwill & Intangibles fell 7.25% year-over-year to $6.0 billion in Q1 2026; TTM through Mar 2026 was $6.0 billion, a 7.25% decrease from a year earlier, with the FY2025 full-year figure at $6.3 billion, down 3.29% from the prior year.
• Goodwill & Intangibles retreated to $6.0 billion in Q1 2026 per JAZZ's latest filing, from $6.3 billion in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $8.6 billion in Q1 2022 and bottomed at $2.5 billion in Q4 2023.
• The 5-year median for Goodwill & Intangibles is $6.9 billion (2024), against an average of $6.7 billion.
• Across the five-year window, Goodwill & Intangibles soared 287.08% in 2022 and sank 66.53% in 2023, its largest moves.
• Year by year, Goodwill & Intangibles stood at $7.5 billion in 2022, then sank by 66.53% to $2.5 billion in 2023, then surged by 158.3% to $6.5 billion in 2024, then retreated by 3.29% to $6.3 billion in 2025, then dropped by 3.99% to $6.0 billion in 2026.
• Per Business Quant, the three latest JAZZ Goodwill & Intangibles figures stand at $6.0 billion (Q1 2026), $6.3 billion (Q4 2025), and $6.4 billion (Q3 2025).